Le Goff, Laure http://orcid.org/0000-0002-4141-0001
Seferian, Andreea
Phelep, Aurelie
Rippert, Pascal
Mathieu, Marie-Laure
Cances, Claude
de Lattre, Capucine
Durigneux, Julien
Gousse, Gaelle
Vincent-Genod, Dominique
Ribault, Shams
Gomez Garcia de la Banda, Marta
Quijano-Roy, Susana
Sarret, Catherine
Servais, Laurent
Vuillerot, Carole
Funding for this research was provided by:
Biogen
Article History
Received: 17 June 2022
Accepted: 9 September 2022
First Online: 29 September 2022
Change Date: 23 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10072-022-06522-w
Declarations
:
: The study was approved by the Ethics Committee of the Hospices Civils de Lyon.
: LS has served as a consultant or advisory board member for Novartis, Novartis Gene Therapies, Cytokinetics, Scholar Rock, Biogen, and Roche. CC has received advisory fees from Novartis Gene Therapies, Roche, and Pfizer and is a site principal investigator for Biogen and Roche clinical trials. LLG has received nonfinancial support from Biogen, Allergan, and Ipsen and consultancy fees from Roche and Novartis Gene Therapies. CV has received grants and advisory fees from Biogen and advisory fees from Roche and Novartis Gene Therapies. SQR is a site principal investigator for clinical trials of Biogen, Novartis Gene Therapies, and Roche has served on advisory boards for Biogen, Novartis Gene Therapies, and Roche, and has received travel and speaker honoraria from Biogen, Novartis and Roche. CS has received advisory fees from Biogen and nonfinancial support from Biogen, Roche and Novartis Gene Therapies. GG and MLM have received nonfinancial support from Biogen. CDL has served as consultant for Biogen and Roche. MGGB has served as consultation for Biogen, Novartis Gene Therapies, and Roche. AP, PR, DVG, SR, JD, and AS declare no competing interests.